HFNC in Management of Bronchiectasis Exacerbation

Launched by ASSIUT UNIVERSITY · Feb 21, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment for patients with bronchiectasis, a condition that affects the lungs and can lead to serious breathing problems. Specifically, the trial is studying the use of High-Flow Nasal Cannula (HFNC) therapy to help manage flare-ups of bronchiectasis that can cause respiratory failure. These flare-ups often require patients to be admitted to the respiratory intensive care unit (RICU) for support. The goal is to see if HFNC can help patients breathe better without needing more invasive forms of ventilation.

To participate in this trial, patients must be between the ages of 18 and 75, have a diagnosis of bronchiectasis, and be in the RICU needing ventilator support but not invasive mechanical ventilation. Unfortunately, those under 18, individuals with certain severe brain injuries, or those who have had prior surgeries like a tracheotomy are not eligible. If you or a loved one qualifies, the trial will provide support and monitoring while testing this new treatment approach. The study is currently recruiting participants, and it aims to improve care for those experiencing difficult breathing due to bronchiectasis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients will be eligible for enrolment if diagnosed with bronchiectasis and admitted to the respiratory intensive care unit (RICU), requiring ventilator support without invasive mechanical ventilation.
• Exclusion Criteria:
• • Age: less than 18 years. Patients with post-arrest encephalopathy. Patient with the previous tracheotomy. Patients who received invasive ventilatory support. Patients with end-organ failure.